Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lexeo Therapeutics, Inc. (LXEO : NSDQ)

• Company Description    Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $9.93 Daily Weekly Monthly 20 Day Moving Average: 1,345,710 shares Shares Outstanding: 72.99 (millions) Market Capitalization: $724.76 (millions) Beta: 1.75 52 Week High: $10.99 52 Week Low: $1.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.24% 9.43% 12 Week 21.10% 19.15% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 345 PARK AVENUE SOUTH FLOOR 6 - NEW YORK,NY 10010 USA ph: 212-547-9879 fax: - investors@lexeotx.com http://www.lexeotx.com

• General Corporate Information    Officers R. Nolan Townsend - Chief Executive Officer and Director Kyle Rasbach - Chief Financial Officer Mette Kirstine Agger - Director Steven Altschuler - Director Paula HJ Cholmondeley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 52886X107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 72.99 Most Recent Split Date: (:1) Beta: 1.75 Market Capitalization: $724.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.51 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 62.92% vs. Previous Quarter: 45.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -90.49 06/30/25 - -94.65 ROA 12/31/25 - - 09/30/25 - -70.86 06/30/25 - -73.36 Current Ratio 12/31/25 - - 09/30/25 - 7.40 06/30/25 - 4.43 Quick Ratio 12/31/25 - - 09/30/25 - 7.40 06/30/25 - 4.43 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 2.20 06/30/25 - 2.56 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.37 06/30/25 - 0.42

Powered by Zacks Investment Research ©